William Blair Investment Management LLC Purchases 101,807 Shares of Haemonetics Co. (NYSE:HAE)

William Blair Investment Management LLC boosted its position in shares of Haemonetics Co. (NYSE:HAE) by 29.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 446,258 shares of the medical instruments supplier’s stock after acquiring an additional 101,807 shares during the period. William Blair Investment Management LLC owned 0.89% of Haemonetics worth $34,844,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust raised its stake in Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 240 shares during the period. AlphaQuest LLC raised its stake in Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after acquiring an additional 1,826 shares during the period. KBC Group NV raised its position in shares of Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock valued at $157,000 after buying an additional 712 shares during the last quarter. iSAM Funds UK Ltd bought a new stake in shares of Haemonetics during the third quarter valued at approximately $204,000. Finally, HighTower Advisors LLC raised its position in shares of Haemonetics by 7.8% during the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier’s stock valued at $262,000 after buying an additional 244 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Down 0.2 %

NYSE HAE opened at $64.69 on Wednesday. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The company has a fifty day moving average of $68.08 and a two-hundred day moving average of $75.26. The firm has a market capitalization of $3.25 billion, a price-to-earnings ratio of 25.47, a PEG ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on HAE. Needham & Company LLC reduced their price objective on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday. Barrington Research reduced their price objective on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. JMP Securities reduced their price objective on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price target on the stock. Finally, Raymond James restated a “strong-buy” rating and issued a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Haemonetics presently has a consensus rating of “Moderate Buy” and a consensus target price of $101.22.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.